Catalent (CTLT) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Catalent, Inc. Reports First Quarter Fiscal Year 2017 Results
November 7, 2016 4:15 PM ESTQ1'17 revenue $442.2 million increased 5% as-reported, or 7% in constant currency from the prior year period. Acquired Pharmatek Laboratories, a West Coast, U.S.-based specialist in drug development and clinical manufacturing; adds extensive formulation and development capabilities. Triphase Accelerator has obtained worldwide rights to an oncology treatment developed using Catalent's proprietary SMARTag technology. Reached an agreement with Moderna Therapeutics to support near-term Good Manufacturing Practice (GMP) efforts for Phase 1/2 clinical studies for its personalized cancer vaccines.... More
